Cytokine blockade - A promising therapeutic option in SLE;Zytokinblockade - Eine vielversprechende therapieoption bei SLE

Zeitschrift fur Rheumatologie

Volumn 67, Issue 4, 2008, Pages 315-317

  Aringer, M ^a   Feierl, E ^b   Smolen, J ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Autoantibodies; Inflammation; Lupus arthritis; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; ATLIZUMAB; AUTOANTIBODY; AZATHIOPRINE; CYTOKINE; GAMMA INTERFERON RECEPTOR; INFLIXIMAB; INTERFERON; INTERLEUKIN 6; MEDI 545; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOPHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 47249145979     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-008-0303-8     Document Type: Article

References (10)

1. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of TNFα blockade in systemic lupus erythematosus - an open label study. Arthritis Rheum 50: 3161-3169
2. Aringer M, Smolen JS (2008) The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 10: 202
3. Aringer M, Steiner G, Graninger WB et al. (2007) Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56: 274-279
4. Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392
5. Blanco P, Palucka AK, Gill M et al. (2001) Induction of dendritic cell differentiation by INF-alpha in systemic lupus erythematosus. Science 294: 1540-1543
6. Illei GG, Yarboro C, Shirota Y et al. (2006) Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. ACR 2006 Program Book Suppl 19
7. Jacob CO, McDevitt HO (1988) Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 331: 356-358
8. Schwarting A, Wada T, Kinoshita K et al. (1998) IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL- Fas(lpr) mice. J Immunol 161: 494-503
9. Tackey E, Lipsky PE, Illei GG (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13: 339-343
10. Wallace DJ, Petri M, Olsen N et al. (2007) MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 56: S526-S527